Same-day antibiotic results from positive blood cultures for hospital labs
TL;DR Ringread helps mid-size hospital microbiology labs report antibiotic susceptibility within hours of a blood culture turning positive, using the published EUCAST rapid method rather than a costly instrument. It supplies setup, training, quality checks and software that alerts the ICU. Hospitals pay a setup fee and a monthly subscription.
Indian ICUs face some of the worst drug resistance anywhere. In ICMR's network of 26 hospitals and 89 ICUs, 72% of Klebsiella and 77% of Acinetobacter bloodstream infections were resistant to carbapenems[1]. With odds like that, can you blame doctors for starting the strongest drugs and waiting? Standard susceptibility testing takes 48–96 hours after a culture flags positive[2]. In a 2026 Indian study, the routine method took about 48 hours to report, against about 23 hours with the rapid method[3]. Every extra day on the wrong drug costs money, side effects and more resistance.
What it does, in regulatory terms: laboratory workflow, quality control and reporting software for a published test method. The lab runs and signs off its own validated test, and the treating doctor decides therapy. If the software later measures zones from images and interprets results, check whether it becomes medical device software under CDSCO's 2026 guidance[4].
EUCAST's rapid method reads disk diffusion plates directly from positive blood culture bottles at 4–8 hours[5]. It needs no new instrument, but labs need training, strict timing, quality control and a way to get results to the ICU quickly. Ringread packages that - a setup visit, a validation protocol against the lab's current method, timers and reading screens at the bench, and alerts to the treating team when results come out.
I reframed the seed, which pitched a new rapid pathogen-identification platform. Instruments that do this already exist, and building another means years of device work and licensing. The cheaper gap is helping the labs that can't buy an instrument.
Private hospitals with 100–300 beds and an in-house microbiology lab pay, through the lab head and the infection-control committee. Accreditation and stewardship programmes give them reasons to show faster reporting. I found no public price for rapid susceptibility instruments in India, so test your pricing against the cost of one extra ICU day.
Indian labs are publishing their own results with the rapid method. A 2026 study from a central Indian hospital paired it with a stewardship bundle and changed therapy in 64.7% of reviewed cases[6]. Another showed results readable at 4 hours for the commonest gram-negative bugs[2]. The method is free to use, so the barrier is execution and not licensing.
There's no public figure for spending on rapid susceptibility testing in Indian hospitals. The narrow signal is clinical - carbapenem resistance above 70% in the main ICU pathogens[1] and a published halving of reporting time[3]. Adjacent - one global diagnostics maker sells an instrument claiming results in an average of 5.5–6 hours[7], showing hospitals in richer markets pay for speed.
Global diagnostics makers sell instruments that test directly from positive blood cultures[7], but they need instrument budgets most mid-size Indian hospitals lack. A Pune startup works on rapid infection and resistance diagnostics[8]. Large teaching hospitals run the rapid method themselves with research staff. The gap is a packaged, supported version for hospitals without either the instrument or the in-house experts.
| Difficulty | Moderate (42/100) |
| Starting capital | ₹45–90 L |
| Time to launch | 6–9 months |
The method is public. The hard part is making it reliable in labs with thin staffing and night shifts, which is most of them, keeping to the organisms and drugs the method covers, and getting ICU doctors to act on early results. Each lab needs its own validation run.
Yes, partly. The software itself may not need a licence today, but the labs you serve work under strict rules and you have to fit inside them.
Building this outside India? The categories above usually have a local equivalent, so check with your own regulator.
Don't let AI read zones or suggest antibiotics until CDSCO's device rules are settled and the method is validated. The lab signs off and the doctor decides therapy.
Want to work out the AI layer for Ringread? Talk to Yash →
I like this for a clinical microbiologist founder with a software partner and hospital lab contacts. If you're hoping to sell an outcome claim then it's not for you. First prove in three labs that results match the standard method and reach the ICU within eight hours of the culture flagging.
Plan for roughly ₹45–90 L, mostly on software, lab setup visits and validation support. You don't build an instrument, which keeps it far below a device company.
Workflow and reporting software isn't a device on its own, but image-based interpretation may be under CDSCO's 2026 guidance. Partner labs also need NABL scope for the method.
Yes, the EUCAST method is published for labs everywhere. Check your local medical software and lab accreditation rules before you sell.
The free Ringread validation kit has the line-by-line capital breakdown, the effort scoring, the lab and software rules checklist, a 14-day validation sprint with pass/fail targets, a 90-day launch plan, 10 interview questions for lab heads and ICU doctors, and 5 assumptions to test. Download the kit →
Thinking about building Ringread or something close to it? The make-or-break work is getting busy labs to run the method on time, every time, and ICU teams to act on it, and that's the kind of rollout I help founders plan. If you need a hand, you know where to find me. Talk to Yash →
For illustration only. Names are fictional and ideas hypothetical; sourced facts are real but may be out of date. Nothing here is legal, financial or professional advice, and Yash Khatri is not personally liable for any use of it. Read the full disclaimer.